Serca Pharmaceuticals showcases exciting data on 13-M at Heart Failure 2023

First-in-class, cardioprotective drug with potential to transform treatment following myocardial infarction and stenting OSLO, Norway, May 22, 2023 /PRNewswire/ — Serca Pharmaceuticals, a Cardioprotection company that is developing 13-M, a novel first in class treatment for minimising…

Leave a Reply

Your email address will not be published. Required fields are marked *